Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) have received a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $46.43.

Several brokerages have recently issued reports on OTLK. Capital One Financial restated an “overweight” rating on shares of Outlook Therapeutics in a report on Friday, February 16th. Brookline Capital Management upgraded shares of Outlook Therapeutics from a “hold” rating to a “buy” rating and set a $31.40 price objective on the stock in a research report on Thursday, January 25th. Chardan Capital upgraded shares of Outlook Therapeutics from a “neutral” rating to a “buy” rating and set a $60.00 target price for the company in a report on Thursday, February 15th. HC Wainwright boosted their price target on Outlook Therapeutics to $30.00 and gave the company a “buy” rating in a report on Monday, March 25th. Finally, Guggenheim raised Outlook Therapeutics from a “neutral” rating to a “buy” rating and set a $40.00 price target for the company in a research report on Thursday, January 25th.

Outlook Therapeutics Trading Down 3.4 %

Shares of NASDAQ:OTLK opened at $8.21 on Wednesday. The stock has a market capitalization of $106.81 million, a P/E ratio of -2.05 and a beta of 0.28. The stock’s 50-day moving average price is $8.53 and its 200-day moving average price is $8.59. Outlook Therapeutics has a 12-month low of $4.00 and a 12-month high of $40.60.

Outlook Therapeutics (NASDAQ:OTLK) last issued its earnings results on Wednesday, February 14th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.20. As a group, research analysts predict that Outlook Therapeutics will post -2.99 EPS for the current year.

Institutional Trading of Outlook Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Gables Capital Management Inc. grew its holdings in shares of Outlook Therapeutics by 132.3% during the 3rd quarter. Gables Capital Management Inc. now owns 154,500 shares of the company’s stock worth $34,000 after acquiring an additional 88,000 shares during the period. Scotia Capital Inc. boosted its position in shares of Outlook Therapeutics by 420.9% during the third quarter. Scotia Capital Inc. now owns 338,439 shares of the company’s stock valued at $75,000 after purchasing an additional 273,463 shares in the last quarter. Finally, Rosalind Advisors Inc. purchased a new stake in Outlook Therapeutics in the first quarter worth $3,723,000. 11.20% of the stock is currently owned by hedge funds and other institutional investors.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.